Related Experiment Video
Updated: Aug 14, 2026
11:29
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Analysis of membrane-bound complement regulatory proteins in prostate cancer
Robert D Loberg1, Kirk J Wojno, LaShon L Day
1Department of Urology, Michigan Urology Center, University of Michigan Health System, Ann Arbor, Michigan 48109-0946, USA. rloberg@umich.edu
Urology
|December 20, 2005
Summary
Membrane-bound complement regulatory proteins (mCRPs) like CD55 and CD97 show increased expression in prostate cancer. This suggests their potential role in cancer development and spread.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Membrane-bound complement regulatory proteins (mCRPs) protect host cells from complement-mediated lysis.
- mCRPs are found in hematopoietic cells and have been observed in various cancers, but their correlation with tumor stage is unclear.
Purpose of the Study:
- To investigate the expression patterns of CD46, CD55, CD59, and CD97 in prostate cancer.
- To determine the correlation between mCRP expression and prostate cancer progression.
Main Methods:
- Tissue microarray analysis of biopsy and autopsy specimens.
- Real-time polymerase chain reaction (PCR) to quantify mRNA expression.
Main Results:
- CD55 and CD97 expression were significantly increased in prostatic intraepithelial neoplasia, localized, and metastatic prostate cancer compared to normal tissues.
- CD46 and CD59 expression showed no significant difference across the stages.
- Real-time PCR confirmed the elevated mRNA levels of CD55 and CD97.
Conclusions:
- mCRPs are differentially expressed in prostate cancer, with CD55 being the primary upregulated mCRP in malignant cells.
- CD97 expression correlates with the malignant phenotype and may influence prostate cancer's tumorigenic and metastatic potential.
